AI model to predict when prostate cancer becomes resistant to hormone therapy
Part of Cancer, Kidney & urinary clinical trials.
This trial is testing whether an artificial intelligence (AI) model can predict how long it takes for intermediate- to high-risk prostate cancer to stop responding to hormone therapy (become castration-resistant). The goal is to help doctors make better treatment decisions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have intermediate- or high-risk prostate cancer
- You have had a prostate biopsy
- You have only been treated with hormone therapy (no other systemic treatments like chemotherapy)
- Your full medical records and biopsy results are available
- You agree to participate and let the researchers use your information
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an artificial intelligence (AI) tool that may improve how doctors detect prostate cancer using imaging and biopsy information. It could help better identify cancer that is suspected based on PSA blood tests and rectal exam findings.
This trial tests if an artificial intelligence system can improve MRI scans used to detect prostate cancer. You may join if your doctor has recommended a prostate biopsy and you have an MRI scan that can be reviewed by both radiologists and AI.
This trial uses artificial intelligence to better predict and treat prostate cancer. If you have a suspected prostate cancer diagnosis, your information may help improve AI-based care.
This study uses an artificial intelligence (AI) system to look at prostate biopsy samples and predict if the cancer has spread to the lymph nodes. It may help doctors decide on the best treatment without needing extra surgery or scans.
This trial uses artificial intelligence to customize your radiation therapy and hormone treatment for high-risk prostate cancer. It aims to improve treatment precision and reduce side effects.
This study uses artificial intelligence to examine MRI and other health data to better predict if high-risk prostate cancer has spread to nearby lymph nodes. Researchers hope this will help guide treatment decisions.
Hear when a new Prostatic Neoplasms, Castration-Resistant trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.